INDEMNIFICATION AGREEMENTIndemnification Agreement • December 13th, 2006 • Oncogenex Technologies Inc • British Columbia
THIS AGREEMENT (the “Agreement”) is made and entered into this day of by and between OncoGenex Technologies Inc. (the “Company”) and (“Indemnitee”).
LICENSE AGREEMENTLicense Agreement • January 29th, 2007 • Oncogenex Technologies Inc • Pharmaceutical preparations • British Columbia
THE UNIVERSITY OF BRITISH COLUMBIA, a corporation continued under the University Act of British Columbia and having its administrative offices at 2075 Wesbrook Mall, in the City of Vancouver, in the Province of British Columbia, V6T 1W5
LICENSE AGREEMENTLicense Agreement • January 29th, 2007 • Oncogenex Technologies Inc • Pharmaceutical preparations • British Columbia
THE UNIVERSITY OF BRITISH COLUMBIA, a corporation continued under the University Act of British Columbia and having its administrative offices at 2075 Wesbrook Mall, in the City of Vancouver, in the Province of British Columbia, V6T 1W5
LICENSE AGREEMENT Between: THE UNIVERSITY OF BRITISH COLUMBIA andLicense Agreement • January 29th, 2007 • Oncogenex Technologies Inc • Pharmaceutical preparations • British Columbia
*Certain information in this exhibit has been omitted as confidential, as indicated by [***]. This information has been filed separately with the Commission.
COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • January 29th, 2007 • Oncogenex Technologies Inc • Pharmaceutical preparations • Delaware
THIS COLLABORATION AND LICENSE AGREEMENT (“Agreement”) is made and entered into effective as of January 5, 2005 (the “Effective Date”), by and among ONCOGENEX TECHNOLOGIES INC., having offices at #400 – 1001 West Broadway, Vancouver, B.C., V6H 4B1 (“OncoGenex”) and ISIS PHARMACEUTICALS, INC., having principal offices at 2292 Faraday Avenue, Carlsbad CA 92008 (“Isis”). OncoGenex and Isis each may be referred to herein individually as a “Party,” or collectively as the “Parties.”
COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • January 29th, 2007 • Oncogenex Technologies Inc • Pharmaceutical preparations • Delaware
THIS COLLABORATION AND LICENSE AGREEMENT (“Agreement”) is made and entered into effective as of August 31, 2003 (the “Effective Date”), by and among ONCOGENEX TECHNOLOGIES INC., having offices at Jack Bell Research Centre, Rm 550, 2660 Oak Street, Vancouver, B.C., V6H 3Z6 (“OncoGenex”) and ISIS PHARMACEUTICALS, INC., having principal offices at 2292 Faraday Avenue, Carlsbad CA 92008 (“Isis”). OncoGenex and Isis each may be referred to herein individually as a “Party,” or collectively as the “Parties.”
GLEAVE SERVICES AGREEMENTOption Agreement • January 29th, 2007 • Oncogenex Technologies Inc • Pharmaceutical preparations • British Columbia
WHEREAS the Corporation has been formed in order to pursue the research, development and commercialization of oncology therapeutics and diagnostics acquired or developed by the Corporation;
CONSULTING AGREEMENTConsulting Agreement • December 13th, 2006 • Oncogenex Technologies Inc • British Columbia
OncoGeneX Technologies Inc., a corporation incorporated pursuant to the laws of the Canada with offices situated at Suite 400, 1001 West Broadway, Vancouver, British Columbia V6H 4B1 (hereinafter referred to as the “Client”)
SECOND AMENDING AGREEMENTSecond Amending Agreement • December 13th, 2006 • Oncogenex Technologies Inc
THE UNIVERSITY OF BRITISH COLUMBIA, a corporation continued under the University Act of British Columbia and having its Industry Liaison offices at #103 – 6190 Agronomy Road, Vancouver, British Columbia, V6T 1Z3
COLLABORATION AND CO-DEVELOPMENT AGREEMENTCollaboration and Co-Development Agreement • January 29th, 2007 • Oncogenex Technologies Inc • Pharmaceutical preparations • British Columbia
THIS COLLABORATION AND CO-DEVELOPMENT AGREEMENT (“Agreement”) is made and entered into effective as of November 16, 2001 (the “Effective Date”), by and among ONCOGENEX TECHNOLOGIES INC., having offices at Suite 400, 609 – 14th Street N.W., Calgary, Alberta T2N 2A1 (“OncoGenex”) and ISIS PHARMACEUTICALS, INC., having principal offices at 2292 Faraday Avenue, Carlsbad CA 92008 (“Isis”). OncoGenex and Isis each may be referred to herein individually as a “Party,” or collectively as the “Parties.”
EMPLOYMENT AGREEMENTOption Agreement • December 13th, 2006 • Oncogenex Technologies Inc • Washington
WHEREAS the Company is a research and development company engaged in clinical research of novel therapeutics for cancer;
FURTHER AMENDED AND RESTATED SHAREHOLDERS’ AGREEMENTAgreement • January 29th, 2007 • Oncogenex Technologies Inc • Pharmaceutical preparations • British Columbia
ONCOGENEX TECHNOLOGIES INC., a corporation incorporated under the laws of Canada and having an office at Suite 400, 1001 West Broadway, Vancouver, British Columbia, V6H 4B1, Facsimile No. (604) 736-3687
SECOND AMENDING AGREEMENTSecond Amending Agreement • January 29th, 2007 • Oncogenex Technologies Inc • Pharmaceutical preparations
THE UNIVERSITY OF BRITISH COLUMBIA, a corporation continued under the University Act of British Columbia and having its Industry Liaison offices at #103 – 6190 Agronomy Road, Vancouver, British Columbia, V6T 1Z3
AGREEMENT OF LEASE OLYMPIC BLOCK BUILDING Between FIRST & YESLER, L.L.C., Landlord and OncoGenex, Inc. September 15, 2005Agreement of Lease • December 13th, 2006 • Oncogenex Technologies Inc
THIS AGREEMENT OF LEASE, made as of the15th day of September, 2005, by and between FIRST & YESLER, L.L.C. (“Landlord”), and OncoGenex , Inc..(“Tenant”).
EMPLOYMENT AGREEMENTOption Agreement • January 29th, 2007 • Oncogenex Technologies Inc • Pharmaceutical preparations • Washington
WHEREAS the Company is a research and development company engaged in clinical research of novel therapeutics for cancer;
EMPLOYMENT AGREEMENTEmployment Agreement • December 13th, 2006 • Oncogenex Technologies Inc • British Columbia
OncoGenex Technologies Inc., a Corporation incorporated under the laws of Canada and having an office at Vancouver, British Columbia
AMENDING AGREEMENTAmending Agreement • January 29th, 2007 • Oncogenex Technologies Inc • Pharmaceutical preparations
This Agreement is signed October 12, 2005 but is deemed to confirm the parties intentions effective as of the 23rd day of November, 2002 (the “Effective Date”).
SECOND AMENDING AGREEMENTSecond Amending Agreement • December 13th, 2006 • Oncogenex Technologies Inc
THE UNIVERSITY OF BRITISH COLUMBIA, a corporation continued under the University Act of British Columbia and having its Industry Liaison offices at #103 – 6190 Agronomy Road, Vancouver, British Columbia, V6T 1Z3
INDEMNITY AGREEMENTIndemnity Agreement • December 13th, 2006 • Oncogenex Technologies Inc • British Columbia
ONCOGENEX TECHNOLOGIES INC., a corporation incorporated under the laws of Canada and having an office at D-9 2733 Heather Street, Vancouver, British Columbia, V5Z 3J5, Facsimile No. (604) 875-5604
GLEAVE SERVICES AGREEMENTAgreement • December 13th, 2006 • Oncogenex Technologies Inc • British Columbia
WHEREAS the Corporation has been formed in order to pursue the research, development and commercialization of oncology therapeutics and diagnostics acquired or developed by the Corporation;
AMENDING AGREEMENTAmending Agreement • December 13th, 2006 • Oncogenex Technologies Inc
This Agreement is signed October 12, 2005 but is deemed to confirm the parties intentions effective as of the 23rd day of November, 2002 (the “Effective Date”).
EMPLOYMENT AGREEMENTEmployment Agreement • January 29th, 2007 • Oncogenex Technologies Inc • Pharmaceutical preparations • British Columbia
OncoGenex Technologies Inc., a Corporation incorporated under the laws of Canada and having an office at Vancouver, British Columbia
ONCOGENEX TECHNOLOGIES INC. 4,500,000 Common Shares UNDERWRITING AGREEMENT Dated: •, 2007Underwriting Agreement • February 23rd, 2007 • Oncogenex Technologies Inc • Pharmaceutical preparations • New York
The undersigned, a shareholder, option holder and/or an officer and/or director of OncoGenex Technologies Inc. (the “Company”) understands that RBC Dominion Securities Inc., RBC Capital Markets Corporation and such other financial institutions as may agree to become underwriters (collectively, the “Underwriters” and each an “Underwriter”) propose to enter into an underwriting or agency agreement (the “Underwriting Agreement”) with the Company, pursuant to which the Company will complete a public offering in Canada and the United States of common shares of its capital stock (the “Common Shares” and such offering the “Offering”).
COLLABORATION AND CO-DEVELOPMENT AGREEMENTCollaboration and Co-Development Agreement • December 13th, 2006 • Oncogenex Technologies Inc • British Columbia
THIS COLLABORATION AND CO-DEVELOPMENT AGREEMENT (“Agreement”) is made and entered into effective as of November 16, 2001 (the “Effective Date”), by and among ONCOGENEX TECHNOLOGIES INC., having offices at Suite 400, 609 – 14th Street N.W., Calgary, Alberta T2N 2A1 (“OncoGenex”) and ISIS PHARMACEUTICALS, INC., having principal offices at 2292 Faraday Avenue, Carlsbad CA 92008 (“Isis”). OncoGenex and Isis each may be referred to herein individually as a “Party,” or collectively as the “Parties.”
EIA AGREEMENTEia Agreement • March 1st, 2007 • Oncogenex Technologies Inc • Pharmaceutical preparations • British Columbia
ONCOGENEX TECHNOLOGIES INC., a corporation formed under the laws of Canada and having an address at Suite 550, 2660 Oak Street, Vancouver, British Columbia, V6H 3Z6 Facsimile No. (604) 736-3687
THIS INDENTURE made as of the 1st day of October, 2004. IN PURSUANCE OF THE “LAND TRANSFER FORM ACT” BETWEEN:Indenture • December 13th, 2006 • Oncogenex Technologies Inc • British Columbia
WITNESSETH that in consideration of the mutual covenants, conditions and agreements herein contained the Landlord and Tenant covenant and agree as follows:
TO BE TYPED ON THE LETTERHEAD OF THE UNIVERSITY OF BRITISH COLUMBIA]Oncogenex Technologies Inc • December 13th, 2006
EMPLOYMENT AGREEMENTAgreement • December 13th, 2006 • Oncogenex Technologies Inc • British Columbia
OncoGenex Technologies Inc., a Corporation incorporated under the laws of Canada and having an office at Vancouver, British Columbia
